Medical Device News Magazine

Stryker Announces First Patient Case Using New Tornier Perform® Patient-Matched Primary Reversed Glenoid

Case to be Presented at 2022 Advanced Shoulder Arthroplasty Meeting on Jan. 21

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Stryker, one of the world’s leading medical technology companies, announced today that its new Tornier Perform® Patient-Matched Primary Reversed Glenoid (Patient-Matched Glenoid) was used in a surgical procedure for the first time.

The case was completed Jan. 13 by Jay Keener, M.D., in St. Louis and will be highlighted in a presentation at the 2022 Advanced Shoulder Arthroplasty (ASAP) Meeting on Jan. 21 in Snowbird, Utah.

The limited-market release Patient-Matched Glenoid is the first surgeon-driven, primary patient-specific implant available in shoulder arthroplasty. Taking into account the surgeon’s surgical preference and patient need, it is a patient-matched implant that is planned on Stryker’s Blueprint® 3D Planning Software.

“The Patient-Matched Glenoid puts surgeons in the driver’s seat to contour the implant to the face of the native glenoid that is unique to each patient’s anatomy,” said Dr. George S. Athwal, one of the designers of the implant system. “The Patient-Matched Glenoid system increases efficiency in the OR, requiring fewer surgical steps and no glenoid bone reaming.”

To generate the Patient-Matched Glenoid, the surgeon uses Blueprint Software to virtually position and execute the creation of a patient-matched implant. Once completed in Blueprint, an order is generated to manufacture the glenoid baseplate and patient-specific instrumentation (PSI). The surgeon will receive the sterile devices and execute the implantation of the baseplate using a ream-free, bone-preserving technique.

“Stryker’s relentless pursuit of innovation is exemplified in the Patient-Matched Glenoid, a strong addition to our upper extremities portfolio,” said Tim Lanier, Vice President & General Manager, Upper Extremities at Stryker. “It will give our customers autonomy that is not available anywhere else in the market.”

To learn more about the presentation discussing the Patient-Matched Glenoid at ASAP on Jan. 21, visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”